Publications by authors named "Daniel Swerdlow"

Claim this Profile
P
Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions.
Lotte M de Boer, Albert Wiegman, Daniel I Swerdlow, John J P Kastelein, Barbara A Hutten

Expert Opin Pharmacother· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Steven E Nissen, Kathy Wolski, Craig Balog, Daniel I Swerdlow, Alison C Scrimgeour

JAMA· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
David A Rider, Mona Eisermann, Kathrin Löffler, Manuela Aleku, Daniel I Swerdlow

Atherosclerosis· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.
Daniel I Swerdlow, David A Rider, Arash Yavari, Marie Wikström Lindholm, Giles V Campion

Cardiovasc Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The genomics of heart failure: design and rationale of the HERMES consortium.
R Thomas Lumbers, Sonia Shah, Honghuang Lin, Tomasz Czuba, Albert Henry, Daniel I Swerdlow

ESC Heart Fail· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mendelian randomization for studying the effects of perturbing drug targets.
Dipender Gill, Marios K Georgakis, Venexia M Walker, A Floriaan Schmidt, Apostolos Gkatzionis, Daniel I Swerdlow

Wellcome Open Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure.
Sonia Shah, Albert Henry, Carolina Roselli, Honghuang Lin, Garðar Sveinbjörnsson, Daniel I Swerdlow

Nat Commun· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.
Amand F Schmidt, Michael V Holmes, David Preiss, Daniel I Swerdlow, Spiros Denaxas

BMC Cardiovasc Disord· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrahepatic Vascular Parasitization by a Hepatocellular Carcinoma.
Marco Ertreo, Daniel R Swerdlow, Alexander Kim, Alexander S Somwaru

Cureus· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.
Seamus C Harrison, Michael V Holmes, Stephen Burgess, Folkert W Asselbergs, Gregory T Jones, Daniel I Swerdlow

JAMA Cardiol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robotic Arm-Assisted Sonography: Review of Technical Developments and Potential Clinical Applications.
Daniel R Swerdlow, Kevin Cleary, Emmanuel Wilson, Bamshad Azizi-Koutenaei, Reza Monfaredi

AJR Am J Roentgenol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Amand F Schmidt, Daniel I Swerdlow, Michael V Holmes, Riyaz S Patel, Zammy Fairhurst-Hunter

Lancet Diabetes Endocrinol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetics of CHD in 2016: Common and rare genetic variants and risk of CHD.
Daniel I Swerdlow, Steve E Humphries

Nat Rev Cardiol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selecting instruments for Mendelian randomization in the wake of genome-wide association studies.
Daniel I Swerdlow, Karoline B Kuchenbaecker, Sonia Shah, Reecha Sofat, Michael V Holmes

Int J Epidemiol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes.
Jon White, Daniel I Swerdlow, David Preiss, Zammy Fairhurst-Hunter, Brendan J Keating

JAMA Cardiol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.
Vinicius Tragante, Folkert W Asselbergs, Daniel I Swerdlow, Tom M Palmer, Jason H Moore

Hum Genet· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis.
Jon White, Reecha Sofat, Gibran Hemani, Tina Shah, Jorgen Engmann, Daniel I Swerdlow

Lancet Diabetes Endocrinol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic insights into statin-associated diabetes risk.
Daniel I Swerdlow, David Preiss

Curr Opin Lipidol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mendelian Randomization and Type 2 Diabetes.
Daniel I Swerdlow

Cardiovasc Drugs Ther· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood Lipids and Type 2 Diabetes Risk: Can Genetics Help Untangle the Web?
Daniel I Swerdlow, Naveed Sattar

Diabetes· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic risk factors and Mendelian randomization in cardiovascular disease.
Daniel I Swerdlow, Aroon D Hingorani, Steve E Humphries

Curr Cardiol Rep· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mendelian randomisation study for statin treatment - Authors' reply.
Daniel I Swerdlow, David Preiss, Aroon D Hingorani, Naveed Sattar

Lancet· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robot-assisted ultrasound imaging: overview and development of a parallel telerobotic system.
Reza Monfaredi, Emmanuel Wilson, Bamshad Azizi Koutenaei, Brendan Labrecque, Kristen Leroy, Daniel Swerdlow

Minim Invasive Ther Allied Technol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Daniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, Michael V Holmes, Jorgen E L Engmann

Lancet· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dysglycaemic effect of statins in diabetes: relevance to clinical practice?
Daniel I Swerdlow, Naveed Sattar

Diabetologia· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis